VSTM

Over the past six months, Verastem's stock (VSTM) experienced an 18.51% decline over the past year, but surged 121% in the past three months due to the commercial traction of AVMAPKI® FAKZYNJA® CO-PACK and the advancement of VS-7375 in cancer studies, also rising 11.90% in the previous week and 21.66% in the last month as of September 24, 2026. In Q1 2026, the company reported $18.7 million in net product revenue for AVMAPKI® FAKZYNJA® CO-PACK, acknowledging 'seasonal headwinds' and 'early commercial execution challenges' but maintaining consistent new patient starts and an expanded prescriber base. Q2 2026 saw strong results with total revenue of $40.1 million, including $25.1 million in net product revenue for AVMAPKI® FAKZYNJA® CO-PACK, a $15 million milestone payment, and a $50 million upfront payment from a non-dilutive royalty financing agreement with Oberland Capital, expected to fund operations into the second half of 2027. Clinical trial progress included dosing the first patient in two Phase 2 trials for VS-7375 in KRAS G12D-mutated metastatic colorectal cancer and advanced non-small cell lung cancer, positive updated results from RAMP 205 for pancreatic cancer, and the FDA granting Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer. Additionally, CFO Daniel Calkins reported selling 55 common shares to cover tax withholding related to restricted stock unit vesting.